

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad · 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

August 13, 2018

Corporate Relationship Department M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) Mumbai -400 051

Scrip Code: **524816** Scrip Code: **NATCOPHARM**

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully

For NATCO Pharma Limited

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fux: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

<u>Ref: PR/ 6 /2018-2019</u> <u>Press Release</u>

Hyderabad, India, August 13th, 2018

Dr.Reddy's & NATCO file Doxorubicin Hydrochloride Liposome Injection in EUROPE

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its codevelopment and marketing partner Dr. Reddy's Laboratories Ltd. has filed for Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil®, for intravenous use, for the European Markets.

Janssen's brand Doxil® is predominantly used for the treatment of metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma. The Doxil® brand, 2mg/ml, had sales of approximately US\$130.5 Million, in Europe, for the 12 months ending December 31, 2017, according to Quintiles IMS.

Forwarded for favour of publication

For NATCO Pharma Limited

M Adinarayana Company Secretary &

Vice President (Legal & Corp Affairs)